Richard Heyman, PhD (Chairman)

Dr. Heyman is an accomplished biotechnology veteran with over 25 years of operational experience. Dr. Heyman was recently the Chairman of Amunix Pharmaceuticals, Inc., which was acquired by Sanofi, and Vividion Therapeutics, which was acquired by Bayer.

Dr. Heyman currently serves on the board of directors for Enliven, ORIC Pharmaceuticals, PMV Pharma, and Vividion Therapeutics. He is also the Vice Chairman of The Salk Institute, on the Board Foundation for the American Association for Cancer Research, and on the executive committee at the University of California San Diego Moores Cancer Center. Previously, Dr. Heyman was the co-founder and CEO of Aragon and Seragon Pharmaceuticals, two San Diego biotech companies focused on discovering and developing therapeutics targeting hormone-dependent cancers. Johnson & Johnson purchased Aragon in 2013 and Genentech/Roche purchased Seragon in 2014. He was an NIH postdoctoral fellow at the Salk Institute, and received a Ph.D. in pharmacology from the University of Minnesota and a B.S. in chemistry from the University of Connecticut.